Shanghai Pulmonary Hospital, Shanghai, China

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

12 drugs in development

Phase 33

Phase 28

Preclinical2

By Therapeutic Area

top 3

Oncology

750%

Metabolic & Endocrine

17%

Respiratory

17%

R&D Momentum

69/100

Pipeline Velocity

36/100

Trial Completion Rate

88/100

Pipeline Concentration

39/100

Pipeline Freshness

62/100

Strategic Signals

↗Active in Metabolic & Endocrine but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Sep 17, 2026

Recruiting

Real-World Efficacy and Safety of Biologics Targeting Type 2 Inflammation Across the Spectrum of Chronic Airway Diseases - A Prospective Observational Study in Asthma and COPD

Sep 16, 2026

Recruiting

A Clinical Study on Inspiratory Flow Rate Capability in Pulmonary Fibrosis Patients

Earlier

Aug 11, 2026TrialA Multicenter, Open-Label, Single-Arm Phase I/II Study of Oral Paclitaxel Solution Combined With an Immune Checkpoint Inhibitor and Concurrent Stereotactic Body Radiotherapy as Neoadjuvant Treatment in Older Patients With Resectable Stage IIA-IIIB Non-Small Cell Lung Cancer

Jul 22, 2026TrialEfficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy vs. Anti-PD-1/PD-L1 Monoclonal Antibody, Chemotherapy, in Combination With Bronchoscopy-assisted Interventional Therapy in the Treatment of Patients With Advanced Central Non-small Cell Lung Cancer, a Randomized Controlled, Prospective Clinical Trial

Jun 24, 2026TrialImpact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function After Thoracoscopic Lung Resection: A Multicenter, Randomized, Double-Blind, Controlled Trial

Feb 21, 2026TrialAcetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)

Feb 1, 2026TrialIntrapleural Bupivacaine Analgesia for Postoperative Pain Management After Minimally Invasive Video-Assisted Thoracoscopic Surgery: A Randomized Controlled Trial

Jan 10, 2026TrialEfficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer

4 more events

Jan 7, 2026TrialIBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer

Jan 1, 2026TrialNeoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

Dec 1, 2025TrialEnsartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC

Oct 1, 2025TrialEfficacy and Safety of Early Antifibrotic Therapy for Non-progressive Fibrotic Interstitial Lung Disease

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

JS004Phase 2

LM-108 antibody and sintilimabPhase 2

LM-108+SintilimabPhase 2

liposomal paclitaxelPhase 2

sintilimab+IBI310+chemotherapyPhase 2

Pancreatic Cancer

JS004Phase 2

Small Cell Lung Cancer

JS004Phase 2

Unknown / Other

Immunotherapy

Vγ2Vδ2 T lymphocyte-based immunotherapyPhase 3

MDR-TB

LithostatPhase 2

Neoadjuvant Treatment

IBI310&SintilimabPhase 3

liposomal paclitaxelPhase 3

Toripalimab

JS004Phase 2

Showing 15 of 16 programs

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)